Overview

A 671-gene solid tumor panel is a large comprehensive profile, and buying it as a service is a procurement decision as much as a clinical one. For distributors, hospitals, and research groups, the right contract depends less on the gene count and more on whether the laboratory can deliver consistent quality, predictable logistics, and a report your team can actually use. This guide frames the sourcing checklist that matters before you sign, so the purchase holds up under real case volume.

How It Works

The service receives a tumor specimen or a stabilized liquid-biopsy sample, extracts nucleic acid, builds a hybrid-capture library across the 671 regions, and sequences them. The provider then returns a consolidated report that groups actionable findings, secondary observations, and a variant-level appendix. From a buyer's view, the important mechanics are the sample kit, the transport window, and the format of the delivered file, because those determine whether the result enters your workflow without manual rework after delivery.

Indications

The broad panel suits programs that want maximum genomic coverage from one assay, including precision-oncology services, large research cohorts, and reference laboratories that re-share results with partners. It is less suited to single-marker questions where a smaller, faster test would do. Procurement teams should match the panel size to the actual case mix, because over-specifying every sample wastes budget while under-specifying forces repeat testing that costs more overall.

Specimen & Reporting

Providers supply collection kits and state the hold time before extraction. Reports arrive as a structured file, often with a summary page plus a full variant table, and the best vendors let you customize which sections travel to the clinician. Confirm the delivery method and the data fields up front, since a 671-gene appendix is only useful if your system can ingest and search it without a separate conversion step.

Storage & Sourcing

Cold-chain logistics dominate the sourcing conversation: kits, transport, and extraction timing must protect nucleic acid across the whole chain. When evaluating a vendor, request evidence of accreditation, a documented validation summary, and a clear turnaround commitment. Negotiate minimum order quantities and batch schedules that fit your volume, and put the unit price, the re-test policy, and the support channel in writing so the service scales without surprises as demand grows.

FAQ

Q: What should a procurement team verify before contracting a 671-gene service? A: Check accreditation, a validation summary, cold-chain logistics, turnaround commitment, report format, minimum order quantity, and the re-test policy, then put price and support terms in writing.

Q: Does a larger gene panel always mean better value? A: Not necessarily. Match the panel size to your case mix; a 671-gene profile suits broad coverage programs, while single-marker questions are cheaper and faster with a smaller assay.

Q: How do logistics affect result quality for this test? A: Nucleic acid degrades if collection, transport, or hold time fall outside the supplier's window, so cold-chain control from kit to extraction is the main safeguard of a reliable 671-gene report.